biotech · Pediatric acute-onset neuropsychiatric syndrome (PANS) · acute hereditary angioedema attacks · MAZE
Maze Therapeutics
Maze Therapeutics patent portfolio — 60 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2018
- Employees
- 152
- Programs
- 8
- Drugs
- 12
- Patents
- 60
Maze Therapeutics patents
60 pharmaceutical patents indexed for Maze Therapeutics. 2 expire within 24 months.
Maze Therapeutics has 60 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 2 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 8372979
Process for the production of high-purity 2,4′-dimethyl-3-piperidino-propiophenone (tolperisone), pharmaceutical compositions that contain the latter, as well as active ingredient formulations that contain tolperisone
granted -
US 8293272
Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
granted -
US 8212029
Method for the production of high-purity 4a, 5, 9, 10, 11, 12,-hexahydro-6H-benzofuro [3a, 3, 2-ef] [2] benzazepine, and the derivatives thereof
granted -
US 7855191
Agent having a destructive effect on malignant tumors and method for the production thereof
granted -
US 7390510
Preparation of hypericin bonded with poly-N-vinylamides
granted -
US 7166588
Derivatives and analogs of galanthamine
granted -
US 6500455
Tolperison-containing, pharmaceutical preparation for oral administration
expired -
US 6426076
Ascorbic acid as an adjuvant in the treatment of malignant tumors using chemotherapy and radiotherapy
expired -
US 6288040
Medicament excipient particles for tissue-specific application of a medicament
expired -
US 6255354
Preparation of a pulmonary surfactant for instillation and oral application
expired -
US 6245362
Medication for treatment of viral disease based on active agents of plant hypericum (St. John's Wort) and method of production of the medication
expired -
US 6228891
Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
expired
Frequently asked questions
How many patents does Maze Therapeutics have?
60 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Maze Therapeutics patents expire?
2 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.